Efficacy of an infant formula manufactured from a specific protein hydrolysate derived from whey protein isolate and concentrate produced by Société des Produits Nestlé S.A. in reducing the risk of developing atopic dermatitis

The European Commission asked EFSA to evaluate the efficacy of an infant formula, containing a specific protein hydrolysate derived from whey protein isolate and concentrate and manufactured by Société des Produits Nestlé S.A., in reducing the risk of developing atopic dermatitis in infants with a f...

Descripción completa

Detalles Bibliográficos
Autores principales: Castenmiller, Jacqueline, Hirsch‐Ernst, Karen‐Ildico, Kearney, John, Knutsen, Helle Katrine, Maciuk, Alexandre, Mangelsdorf, Inge, McArdle, Harry J, Naska, Androniki, Pelaez, Carmen, Pentieva, Kristina, Siani, Alfonso, Thies, Frank, Tsabouri, Sophia, Turck, Dominique, Vinceti, Marco, Marchelli, Rosangela, van Loveren, Henk, Dumas, Céline, Titz, Ariane, de Henauw, Stefaan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Scientific Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207397/
https://www.ncbi.nlm.nih.gov/pubmed/34140987
http://dx.doi.org/10.2903/j.efsa.2021.6603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207397/
https://www.ncbi.nlm.nih.gov/pubmed/34140987
http://dx.doi.org/10.2903/j.efsa.2021.6603

Ejemplares similares